{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:48Z","timestamp":1792178988146,"version":"4.4.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.autrev.2025.103879","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:36:42Z","timestamp":1752608202000},"page":"103879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC)"],"prefix":"10.1016","volume":"24","author":[{"given":"Nantakarn","family":"Pongtarakulpanit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Keret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidehi","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Boz\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengappa","family":"Kavadichanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Leclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Bishnoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Ardalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Conticini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yuan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Y.K.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rosina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belina Y.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Lilleker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Dourado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek C.","family":"Gandiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103879_bb0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0010","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/1756-185X.13559","article-title":"Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry","volume":"22","author":"Nuno-Nuno","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00296-020-04779-y","article-title":"Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort","volume":"41","author":"Naveen","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103879_bb0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0025","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"A. British Society for Rheumatology standards and G. Guidelines Working, British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0030","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: Management of Refractory Inflammatory Myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0000000000000958","article-title":"Exploring challenges in the management and treatment of inclusion body myositis","volume":"35","author":"Skolka","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0040","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103879_bb0045","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease, N","volume":"391","author":"Hagen","year":"2024","journal-title":"Engl J Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0055","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/annrheumdis-2018-214868","article-title":"Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status","volume":"78","author":"Boeters","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease-A case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0065","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"O. Paediatric rheumatology international trials, the PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0070","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0075","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/key421","article-title":"Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis","volume":"58","author":"Rosina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003093","article-title":"O. Paediatric rheumatology international trials, defining criteria for disease activity states in juvenile dermatomyositis based on the juvenile dermatomyositis activity index","volume":"10","author":"Rosina","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103879_bb0085","first-page":"202","article-title":"The Myositis clinical trials consortium: an international collaborative initiative to promote clinical trials in adult and juvenile myositis","volume":"43","author":"Bishnoi","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0090","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103879_bb0095","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile Myositis","volume":"30","author":"Rider","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0100","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0115","unstructured":"W.K. Locklear T, Resource chapters: patient-reported outcomes, in: Book Resource chapters: patient-reported outcomes, pp."},{"key":"10.1016\/j.autrev.2025.103879_bb0120","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3899\/jrheum.161252","article-title":"Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An international Delphi study","volume":"44","author":"Park","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0125","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s10067-016-3234-9","article-title":"Poor agreement of objectively measured and self-reported physical activity in juvenile dermatomyositis and juvenile systemic lupus erythematosus","volume":"35","author":"Pinto","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0130","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1093\/rheumatology\/kead316","article-title":"Discordance between patient- and physician-reported disease activity in adult idiopathic inflammatory myopathy","volume":"62","author":"Keret","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103879_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152111","article-title":"Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: international study from the OMERACT myositis working group","volume":"58","author":"DiRenzo","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0140","first-page":"539","article-title":"Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy, Semin","volume":"51","author":"Saygin","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0150","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0160","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/bjd\/ljad133","article-title":"A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis","volume":"189","author":"Dan","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103879_bb0175","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/annrheumdis-2023-eular.2111","article-title":"POS1240\u00a0efficacy and safety of abatacept in myositis associated interstitial lung disease","volume":"82","author":"Aggarwal","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0180","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive Fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0185","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12890-024-03314-0","article-title":"Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease","volume":"24","author":"Aggarwal","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0190","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kel017","article-title":"Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis","volume":"45","author":"Agarwal","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0195","article-title":"Functional measures and patient home self-assessments in the idiopathic inflammatory myopathies [abstract]","volume":"69","author":"Kocoloski","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nmd.2016.05.014","article-title":"213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015","volume":"26","author":"Benveniste","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2025.103879_bb0205","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0210","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0215","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of Lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: A randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0220","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD)-report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103879_bb0225","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0230","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2025.103879_bb0235","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/rheumatology\/kew213","article-title":"Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients","volume":"55","author":"Nagaraju","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103879_bb0240","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874312901206010054","article-title":"Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups","volume":"6","author":"Volochayev","year":"2012","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.autrev.2025.103879_bb0245","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12954","article-title":"MRI and muscle imaging for idiopathic inflammatory myopathies","volume":"31","author":"Malartre","year":"2021","journal-title":"Brain Pathol"},{"key":"10.1016\/j.autrev.2025.103879_bb0250","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000093866","article-title":"Needle electromyographic findings in 98 patients with myositis","volume":"55","author":"Blijham","year":"2006","journal-title":"Eur Neurol"},{"key":"10.1016\/j.autrev.2025.103879_bb0255","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13317-014-0062-2","article-title":"Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis","volume":"5","author":"Vattemi","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.autrev.2025.103879_bb0260","series-title":"Managing myositis: A Practical Guide","first-page":"125","article-title":"Making the diagnosis of Myositis: Skin biopsy and interpretation","author":"Sander","year":"2019"},{"key":"10.1016\/j.autrev.2025.103879_bb0265","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0270","first-page":"S-1-6","article-title":"Complexities in defining remission in rheumatic diseases","volume":"24","author":"Pincus","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"2021","key":"10.1016\/j.autrev.2025.103879_bb0275","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0285","first-page":"20","article-title":"The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life, Semin","volume":"49","author":"Scott","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12325-021-01946-w","article-title":"Value of remission in patients with rheumatoid arthritis: A targeted review","volume":"39","author":"Ostor","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2025.103879_bb0295","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10067-019-04600-7","article-title":"Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy","volume":"38","author":"Ten Klooster","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0300","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0305","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0310","article-title":"Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103879_bb0315","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0320","doi-asserted-by":"crossref","unstructured":"P. Studenic, D. Aletaha, M. de Wit, T.A. Stamm, F. Alasti, D. Lacaille, J.S. Smolen and D.T. Felson, American College of Rheumatology\/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision Arthritis Rheumatol 75 (2023) 15\u201322.","DOI":"10.1002\/art.42347"},{"key":"10.1016\/j.autrev.2025.103879_bb0325","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0330","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103879_bb0335","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0340","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0345","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0350","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0355","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"S. Assessment of SpondyloArthritis international, ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0360","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0365","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103879_bb0370","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3899\/jrheum.181472","article-title":"Treating psoriatic arthritis to target: defining psoriatic arthritis disease activity score that reflects state of minimal disease activity","volume":"47","author":"Perruccio","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0380","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103879_bb0390","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/annrheumdis-2021-220363","article-title":"Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity","volume":"80","author":"Jesus","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0395","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0400","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0405","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0410","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2010.133850","article-title":"International work group for and Gca, definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus","volume":"70","author":"Dejaco","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0415","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises","volume":"vol. 68","author":"de Lautour","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2025.103879_bb0420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis","volume":"55","author":"T.F.o.T.M.S.A.B.o.t.M.G.F.o. America","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103879_bb0425","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103879_bb0430","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2025.103879_bb0435","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103879_bb0440","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2025.103879_bb0445","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2025.103879_bb0450","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"European league against rheumatism\/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0455","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0460","first-page":"586","article-title":"Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis\/dermatomyositis","volume":"59","author":"Watanabe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0465","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2377-11-143","article-title":"Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China","volume":"11","author":"Shu","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2025.103879_bb0470","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936822","article-title":"Prognostic factors for steroid-free remission in patients with idiopathic inflammatory myopathies: importance of anthropometric measurements","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0475","first-page":"309","article-title":"Anti-MDA5-positive dermatomyositis and remission in a single referral Centre population","volume":"41","author":"Tiniakou","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0480","first-page":"1607","article-title":"AB0623\u00a0rate and predictive factors associated with sustained remission in idiopathic inflammatory myositis","volume":"79","author":"Vojinovic","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0485","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/ard.2005.045690","article-title":"Long-term outcome in polymyositis and dermatomyositis","volume":"65","author":"Bronner","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0490","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0495","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/acr.24980","article-title":"Cessation of immunomodulatory medication use in dermatomyositis: A single-center cohort study","volume":"75","author":"Cho","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2025.103879_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103435","article-title":"Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort study","volume":"154","author":"Chen","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103879_bb0505","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0510","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/41.1.22","article-title":"Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality","volume":"41","author":"Sultan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0515","doi-asserted-by":"crossref","first-page":"1429010","DOI":"10.3389\/fimmu.2024.1429010","article-title":"Altered metabolic profiles of dermatomyositis with different myositis-specific autoantibodies associated with clinical phenotype","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103879_bb0520","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0525","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103879_bb0530","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e335","article-title":"Efficacy and safety of rituximab in Korean patients with refractory inflammatory myopathies","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.autrev.2025.103879_bb0535","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s10067-024-07019-x","article-title":"Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)-a retrospective analysis from Indian Myositis registry (MyoIN)","volume":"43","author":"Shobha","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0540","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard.52.12.857","article-title":"Adult onset polymyositis\/dermatomyositis: clinical and laboratory features and treatment response in 75 patients","volume":"52","author":"Koh","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0545","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2025.103879_bb0550","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0555","first-page":"689","article-title":"Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the rituximab in Myositis trial","volume":"32","author":"Rider","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0560","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005694","article-title":"Atorvastatin-induced necrotizing autoimmune myositis: an emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype","volume":"96","author":"Troyanov","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103879_bb0565","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/1756-185X.14903","article-title":"Observational longitudinal study to assess the outcome of patients with idiopathic inflammatory myositis using validated tools","volume":"26","author":"Shukla","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0570","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0575","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for Myositis","volume":"4","author":"Barsotti","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0580","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/art.23963","article-title":"Reliability and validity of the myositis disease activity assessment tool","volume":"58","author":"Sultan","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103879_bb0585","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102234","article-title":"Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study","volume":"64","author":"Werth","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2025.103879_bb0595","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0600","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CM9.0000000000002788","article-title":"Vasculopathy in dermatomyositis","volume":"137","author":"Xu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.autrev.2025.103879_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103335","article-title":"The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: A systematic review and meta-analysis","volume":"22","author":"Wang","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103879_bb0610","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for Myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103879_bb0615","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103879_bb0620","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0889-857X(02)00032-7","article-title":"Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies","volume":"28","author":"Targoff","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2025.103879_bb0625","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/annrheumdis-2024-eular.4803","article-title":"OP0042\u00a0normal CREATINE kinase in idiopathic inflammatory myopathies-disease characteristics and outcomes","volume":"83","author":"Keret","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103879_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/cdli.2.1.1-9.1995","article-title":"Laboratory evaluation of the inflammatory myopathies","volume":"2","author":"Rider","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.autrev.2025.103879_bb0635","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004344","article-title":"Creatine kinase in the U.S. population: impact of demographics, comorbidities, and body composition on the normal range","volume":"95","author":"George","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103879_bb0640","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/01.CON.0000511070.50715.ab","article-title":"Autoimmune Myopathies","volume":"22","author":"Mammen","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.autrev.2025.103879_bb0645","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-019-0878-x","article-title":"Arthritis in idiopathic inflammatory myopathies","volume":"21","author":"Klein","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103879_bb0650","series-title":"Gastrointestinal Involvement in Inflammatory Myositis","first-page":"263","author":"Novo","year":"2017"},{"key":"10.1016\/j.autrev.2025.103879_bb0655","first-page":"322","article-title":"Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-Centre cohort","volume":"41","author":"Guimar\u00e3es","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103879_bb0660","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2010.08.013","article-title":"Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review","volume":"148","author":"Gupta","year":"2011","journal-title":"Int J Cardiol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:13:35Z","timestamp":1764648815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1568997225001399"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103879","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC)","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103879"}}